New therapeutic approaches for solid tumors: Histone deacetylase, methyltransferase and proteasome inhibitors

JDDG - Journal of the German Society of Dermatology

Volumn 4, Issue 2, 2006, Pages 108-113

  Becker, Jürgen C ^a   Ugurel, Selma ^b   Bröcker, Eva Bettina ^a   Schrama, David ^a   Houben, Roland ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Cancer stem cells; Epigenetic regulation; Tumor suppressor gene

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BORTEZOMIB; CYTIDINE DERIVATIVE; FK 288; FR 901228; HISTONE DEACETYLASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; PROTEASOME INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID; VALPROIC ACID; ANTINEOPLASTIC AGENT; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE; METHYLTRANSFERASE; PROTEASOME;

CARCINOGENESIS; CYTOGENETICS; DNA METHYLATION; GENE EXPRESSION; GENE TARGETING; HUMAN; NONHUMAN; REVIEW; RNA TRANSLATION; SOLID TUMOR; TUMOR GROWTH; ARTICLE; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MELANOMA; SKIN TUMOR;

ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; DNA MODIFICATION METHYLASES; HISTONE DEACETYLASES; HUMANS; MELANOMA; METHYLTRANSFERASES; PROTEASOME ENDOPEPTIDASE COMPLEX; SKIN NEOPLASMS;

EID: 33645215148     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2006.05920.x     Document Type: Review

References (31)

1. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-421.
2. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-360.
3. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A, Spriggs DR. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8: 2505-2511.
4. Al Hajj M, Becker MW, Wicha M, Weissman I, Clarke MF. Therapeutic implications of cancer stem cells. Curr Opin Genet Dev 2004; 14: 43-47.
5. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, Graff JR. Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 1999; 59: 798-802.
6. Boukamp P. UV-induced skin cancer: similarities-variations. J Dtsch Dermatol Ges 2005; 3: 493-503.
7. Chudnovsky Y, Khavari PA, Adams AE. Melanoma genetics and the development of rational therapeutics. J Clin Invest 2005; 115: 813-824.
8. DeBaun MR. Issues regarding study design for initial clinical trials using decitabine. Semin Hematol 2004; 41: 23-27.
9. Denlinger CE, Rundall BK, Jones DR. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. J Thorac Cardiovasc Surg 2004; 128: 740-748.
10. Eastman A. Cell cycle checkpoints and their impact on anticancer therapeutic strategies. J Cell Biochem 2004; 91: 223-231.
11. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 2002; 21: 5427-5440.
12. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol 2002; 196: 1-7.
13. Flaherty KT. New molecular targets in melanoma. Curr Opin Oncol 2004; 16: 150-154.
14. Gottlicher M. Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol 2004; 83: S91-S92.
15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
16. Insinga A, Monestiroli S, Ronzoni S, Gelmetti V, Marchesi F, Viale A, Altucci L, Nervi C, Minucci S, Pelicci PG. Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway. Nat Med 2005; 11: 71-76.
17. Issa JP, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, Talpaz M, Garcia-Manero G, Kantarjian HM. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005; 23: 3948-3956.
18. Kanai Y, Hui AM, Sun L, Ushijima S, Sakamoto M, Tsuda H, Hirohashi S. DNA hypermethylation at the D17S5 locus and reduced HIC-1 mRNA expression are associated with hepatocarcinogenesis. Hepatology 1999; 29: 703-709.
19. Karpf AR, Jones DA. Reactivating the expression of methylation silenced genes in human cancer. Oncogene 2002; 21: 5496-5503.
20. Leonhardt H, Cardoso MC. DNA methylation, nuclear structure, gene expression and cancer. J Cell Biochem 2000; 35: 78-83.
21. Marks PA, Richon VM, Kelly WK, Chiao JH, Miller T. Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp 2004; 259: 269-281.
22. McLaughlin F, La Thangue NB. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem Pharmacol 2004; 68: 1139-1144.
23. Piekarz R, Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004; 10: 2289-2298.
24. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature 2001; 414: 105-111.
25. Samlowski WE, Leachman SA, Wade M, Cassidy P, Porter-Gill P, Busby L, Wheeler R, Boucher K, Fitzpatrick F, Jones DA, Karpf AR. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005; 23: 3897-3905.
26. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE. Loss of pRb expression in pituitary adenomas is associated with methylation of the RB1 CpG island. Cancer Res 200; 60: 1211-1216.
27. Steiner FA, Hong JA, Fischette MR, Beer DG, Guo ZS, Chen GA, Weiser TS, Kassis ES, Nguyen DM, Lee S, Trepel JB, Schrump DS. Sequential 5-Aza 2′-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 2005; 24: 2386-2397.
28. Stromblad S, Becker JC, Yebra M, Brooks PC, Cheresh DA. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. J Clin Invest 1996; 98: 426-433.
29. Villar-Garea A, Esteller M. Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int J Cancer 2004; 112: 171-178.
30. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-799.
31. Wales MM, Biel MA, el Deiry W, Nelkin BD, Issa JP, Cavenee WK, Kuerbitz SJ, Baylin SB. p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. Nat Med 1995; 1: 570-577.